what are glp 1 drugs made from The GLP-1 weight loss revolution | Feature The GLP-1 revolution: What UAB

Current Therapeutic Research 1986;39(3):429-435

Among the drugs targeting Gln transporters for DSMTs treatment, only the LAT1 inhibitor JPH203 has entered clinical trials

Under physiological conditions, cells have to perform a delicate balancing act of preventing excess accumulation of ROS while simultaneously preventing excess depletion of ROS, and these demands could be exacerbated by disease or abnormalities associated with aging

The clinical takeaway is clear: risk stratificationincluding BMI, inflammatory status, and lipid profileshould play a central role in guiding personalized lipid-lowering therapy, particularly in patients with high residual risk despite standard treatment